Expertise in
15
conditions

Dr. David L. Watkins

Oncology
Texas Oncology Pharmacy-Midland
400 Rosalind Redfern Grover Pkwy Ste 100, 
Midland, TX 
Accepting New Patients
Offers Telehealth
Expertise in
15
conditions
Texas Oncology Pharmacy-Midland
400 Rosalind Redfern Grover Pkwy Ste 100, 
Midland, TX 

Overview

David Watkins is an Oncologist practicing medicine in Midland, Texas.

Dr. Watkins is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Paget Disease of the Breast, Breast Cancer, and Squamous Cell Lung Carcinoma.

He is actively involved in clinical research, participating in 7 clinical trials. Dr. Watkins is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in TX

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Moda Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO

Locations

Texas Oncology Pharmacy-Midland
400 Rosalind Redfern Grover Pkwy Ste 100, Midland, TX 79701

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials
Similar Doctors
Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Texas Oncology Pharmacy-Odessa

500 W 3rd St, 
Odessa, TX 
 (19.9 miles away)
432-335-8275
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Renuka Borra is an Oncologist practicing medicine in Odessa, Texas. Dr. Borra is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Familial Colorectal Cancer, Colorectal Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Bone Marrow Aspiration. Dr. Borra is currently accepting new patients.

Expertise in
6
conditions
Expertise in
6
conditions
Referral may be required

Texas Oncology Pharmacy-Odessa

500 W 3rd St, 
Odessa, TX 
 (19.9 miles away)
432-335-8275
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Timothy George is an Oncologist practicing medicine in Odessa, Texas. Dr. George is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Pleuropulmonary Blastoma, and Paget Disease of the Breast. Dr. George is currently accepting new patients.

Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required

Ashutosh Rastogi MDPA Inc.

5813 W Wadley Ave, 
Midland, TX 
 (5.1 miles away)
432-570-0052
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Ashutosh Rastogi is an Oncologist practicing medicine in Midland, Texas. Dr. Rastogi is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Chronic Lymphocytic Leukemia (CLL), and Chronic B-Cell Leukemia (CBCL). Dr. Rastogi is currently accepting new patients.

Frequently Asked Questions about Dr. David L. Watkins

How do I make an appointment with Dr. David L. Watkins?

You can book an appointment with Dr. David L. Watkins by calling their office at 432-687-1949. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David L. Watkins a top-rated expert for Pleuropulmonary Blastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David L. Watkins is classified as an Distinguished expert for Pleuropulmonary Blastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David L. Watkins specialize in?

While Dr. David L. Watkins is a Oncology, they have specific expertise in Pleuropulmonary Blastoma, Paget Disease of the Breast, and Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. David L. Watkins accept my insurance?

Dr. David L. Watkins accepts most major insurance plans, including Cigna and Friday Health. We recommend calling the office directly at 432-687-1949 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Watkins's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 8 Advanced Conditions
    View All 42 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile